News
XFOR
1.105
-1.34%
-0.015
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
X4 Pharmaceuticals Price Target Raised to $5.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
Benzinga · 1d ago
Buy Rating Affirmed for X4 Pharmaceuticals’ Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
TipRanks · 1d ago
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
X4 Pharmaceuticals, Inc. Received FDA approval for mavorixafor in WHIM syndrome. The drug has the potential to improve the health of patients with the rare genetic syndrome. I believe the market is underreacting to the potential of the drug. The major risk for X4 is setbacks with insurance coverage policies.
Seeking Alpha · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-3M, Phibro Animal Health, copper miners
Dow Jones Industrial Average was up 0.32% in volatile trading on Monday. Shares of Tesla and Apple advanced. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. The top three S&P 500 percentage gainers were Tesla, Apple and Domino's Pizza.
Reuters · 2d ago
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder
FDA approves X4 Pharmaceuticals Inc’s Xolremdi for use in patients with WHIM syndrome. The drug aims to increase the number of circulating mature neutrophils and lymphocytes. The FDA approved the drug based on 4WHIM Phase 3 trial results.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Revvity, Southern Co, Duke Energy
Wall Street's main indexes crept higher in volatile trading on Monday. Shares of Tesla and Apple advanced. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. Revvity, Southern Co, Duke Energy were among the stocks on the move. The Dow Jones Industrial Average was up 0.20% in early trading.
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Fulton, Deciphera Pharmaceuticals, VivoPower
U.S. Stocks were poised for a higher open on Monday. Tesla and Apple led gains in megacap companies. Investors exercised caution ahead of the Federal Reserve's interest rate decision later in the week. Dow e-minis were up 0.14% in early trading.
Reuters · 2d ago
X4 Pharmaceuticals: XOLREMDI FDA Approval and Launch Update
TipRanks · 2d ago
X4 PHARMACEUTICALS INC - SET WHOLESALE ACQUISITION COST FOR XOLREMDI ON AN ANNUAL BASIS TO $496,400 FOR PATIENTS GREATER THAN 50 KILOGRAMS
Reuters · 2d ago
X4 PHARMACEUTICALS INC - SET A WHOLESALE ACQUISITION COST FOR XOLREMDI ON AN ANNUAL BASIS TO $372,300 FOR PATIENTS LESS THAN OR EQUAL TO 50 KILOGRAMS
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Apple, Domino's
U.S. Stock index futures edged higher on Monday. Tesla and Apple led gains in megacap companies. Investors exercise caution ahead of the Federal Reserve's interest rate decision later in the week. Dow e-minis were up 0.17% in early trading.
Reuters · 2d ago
BUZZ-X4 Pharmaceuticals rises as US FDA approves immunodeficiency therapy
X4 Pharmaceuticals' XFOR.O shares rise 9.9% to $1.29 premarket. US FDA approves immunodeficiency therapy to treat WHIM syndrome. First of its kind to get U.S. Approval specifically for treatment of the rare genetic disease.
Reuters · 2d ago
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules
FDA approves Xolremdi capsules for use in patients with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes. X4 Pharmaceuticals says it is the first therapy specifically indicated for patients with the rare condition. The company says the body's immune system does not function properly.
Dow Jones · 2d ago
UPDATE 3-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease. First therapy to get U.S. Approval specifically for the treatment of WHIM syndrome. Shares of the company were up 2% in premarket trading. X4's mavorixafor approved to treat rare genetic immunodeciciency disease in patients 12 years of age and older.
Reuters · 2d ago
X4 Pharmaceuticals Launches XOLREMDI with FDA Approval
TipRanks · 2d ago
X4 PHARMACEUTICALS SHARES RISE 12.5% PREMARKET AFTER US FDA APPROVES CO'S IMMUNODEFICIENCY DRUG
Reuters · 2d ago
US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease
Reuters · 2d ago
X4 PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF XOLREMDI™ (MAVORIXAFOR) CAPSULES, FIRST DRUG INDICATED IN PATIENTS WITH WHIM SYNDROME
Reuters · 2d ago
More
Webull provides a variety of real-time XFOR stock news. You can receive the latest news about X4 Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About XFOR
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.